Literature DB >> 28085015

Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer.

Zhiliang Huang1,2, Zenan Ai1, Nan Li1,2, Haofeng Xi1, Xucan Gao1, Feng Wang1, Xiaojun Tan3, Haiying Liu1,2.   

Abstract

BACKGROUND: Over expression of galectin-3 (gal-3) has been associated with tumor invasion and distant metastases, but few reports investigated the relation between gal-3 expression and prognosis in stage II colon cancer.
OBJECTIVE: We studied the expressions of gal-3, E-cadherin, and vimentin in stage II colon cancer to identify predictive factors of clinical outcome.
METHODS: Clinical and laboratory data from 117 consecutive patients of stage II colon cancer during 2008-2010 were collected and analyzed retrospectively. Expressions of gal-3, E-cadherin, and vimentin in tumor tissue were investigated by immunohistochemistry. Potential correlations between these markers and various clinicopathological parameters as well as clinical outcomes were studied. Human colon cancer cell line SW480 was used to test the epithelial-mesenchymal transition (EMT) inducing effects of gal-3 in vitro.
RESULTS: High expression of tumoral gal-3 was associated with tumor size, poor differentiation and negatively related to low E-cadherin expression. Compare with adjacent normal colon tissue, most tumor tissues strongly expressed gal-3 and vimentin, but had lower E-cadherin expression. Univariate analysis showed that expressions of gal-3 and vimentin in tumor were predictors of tumor recurrence and overall survival. Multivariate analysis revealed that tumoral gal-3 expression was the only independent predictor of both tumor recurrence and overall survival after resection. Cell experiments and western blotting showed exogenous gal-3 could induce SW480 cells become more aggressive and express more hallmarks of EMT.
CONCLUSIONS: Galectin-3 may be a useful marker for identification of poor prognosis in stage II colon cancer. Cell experiments and western blotting showed exogenous gal-3 could induce SW480 cells become more aggressive and express more hallmarks of EMT.

Entities:  

Keywords:  E-cadherin; Galectin-3; colon cancer; prognosis; vimentin

Mesh:

Substances:

Year:  2016        PMID: 28085015     DOI: 10.3233/CBM-160661

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  β3GnT8 Promotes Colorectal Cancer Cells Invasion via CD147/MMP2/Galectin3 Axis.

Authors:  Zhi Jiang; Huan Zhang; Chunliang Liu; Jun Yin; Shan Tong; Junxing Lv; Shaohua Wei; Shiliang Wu
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

Review 2.  Galectins as Molecular Targets for Therapeutic Intervention.

Authors:  Ruud P M Dings; Michelle C Miller; Robert J Griffin; Kevin H Mayo
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

3.  Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas.

Authors:  Falk Wehrhan; Maike Büttner-Herold; Luitpold Distel; Jutta Ries; Patrick Moebius; Raimund Preidl; Carol I Geppert; Friedrich W Neukam; Marco Kesting; Manuel Weber
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

4.  Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies.

Authors:  Yi Wang; Shiwei Liu; Ye Tian; Yamin Wang; Qijie Zhang; Xiang Zhou; Xianghu Meng; Ninghong Song
Journal:  Cancer Cell Int       Date:  2018-11-03       Impact factor: 5.722

5.  High Vimentin Expression Predicts a Poor Prognosis and Progression in Colorectal Cancer: A Study with Meta-Analysis and TCGA Database.

Authors:  Le Du; Jingchuan Li; Lei Lei; Hongjuan He; Erfei Chen; Jing Dong; Jin Yang
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

6.  MCP mediated active targeting calcium phosphate hybrid nanoparticles for the treatment of orthotopic drug-resistant colon cancer.

Authors:  Shaobo Bai; Yang Sun; Ying Cheng; Weiliang Ye; Chenchao Jiang; Miao Liu; Qifeng Ji; Bangle Zhang; Qibing Mei; Daozhou Liu; Siyuan Zhou
Journal:  J Nanobiotechnology       Date:  2021-11-17       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.